

VIEWPOINTS

Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment

Analia I. Porrás^{1*}, Zaida E. Yadon¹, Jaime Altcheh², Constança Britto³, Gabriela C. Chaves⁴, Laurence Flevaud⁵, Olindo Assis Martins-Filho⁶, Isabela Ribeiro⁷, Alejandro G. Schijman⁸, Maria Aparecida Shikanai-Yasuda⁹, Sergio Sosa-Estani¹⁰, Eric Stobbaerts⁷, Fabio Zicker¹¹

1 Pan American Health Organization, Regional Office of the World Health Organization, Washington, D.C., United States of America, **2** Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina, **3** Laboratório de Biologia Molecular e Doenças Endêmicas, Oswaldo Cruz Institute, Laboratory of Molecular Biology and Endemic Diseases, FIOCRUZ, Rio de Janeiro, Brazil, **4** Sergio Arouca National School of Public Health, FIOCRUZ, Rio de Janeiro, Brazil, **5** Médecins Sans Frontières—Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA), Barcelona, Spain, **6** René Rachou Research Center, Laboratory of Biomarkers of Diagnostic and Monitoring, Oswaldo Cruz Institute, Minas Gerais, Brazil, **7** Latin America Regional Office, Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil, **8** Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr Hector Torres” (INGEBI-CONICET), Buenos Aires, Argentina, **9** Department of Infectious and Parasitic Diseases, Faculdade de Medicina, University of São Paulo, Sao Paulo, Brazil, **10** Instituto Nacional de Parasitología, Dr. Mario Fátala Chaben ANLIS, Ministerio de Salud, Buenos Aires, Argentina, **11** Center for Technological Development in Health, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro, Brazil



OPEN ACCESS

Citation: Porrás AI, Yadon ZE, Altcheh J, Britto C, Chaves GC, Flevaud L, et al. (2015) Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment. *PLoS Negl Trop Dis* 9(6): e0003697. doi:10.1371/journal.pntd.0003697

Editor: Alain Debrabant, US Food and Drug Administration, UNITED STATES

Published: June 4, 2015

Copyright: © 2015 Porrás et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The meeting was supported by Pan-American Health Organization and The Special Programme for Research and Training in Tropical Diseases (TDR). SSE and AGS are members of the Carrera de Investigador Científico, from the Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* porrasan@paho.org

Introduction

Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin America, where it is endemic in all countries. With an overall estimate of 65 million people at risk of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Switzerland [9,10], and France [11] have experienced the occurrence of *Trypanosoma cruzi*-infected and Chagas disease cases; the majority of these cases are among immigrants coming from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs), Chagas disease affects mostly poor populations with limited access to health services. Vector transmission is associated with poor housing in periurban and rural areas. After infection, the disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%–30% of the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining infected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactivation of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS, organ transplants, or immunosuppressive therapy [14].

Following resolutions from the Pan American Health Organization (PAHO) and World Health Organization (WHO) on the prevention, care, and control of Chagas disease, several countries in the Americas have strengthened control activities and achieved significant progress towards this goal. Yet, the disease remains prevalent among marginalized populations in

the continent; many patients remain undiagnosed and untreated, making Chagas disease the NTD with the highest burden in Latin America countries. In addition, infected and diseased individuals are increasingly diagnosed in different parts of the world [15].

Case management and treatment are essential strategies to eliminate Chagas disease as a public health problem. However, ensuring diagnosis and access to treatment for millions of infected people continues to be a challenge. Timely diagnosis and trypanocidal treatment are known to reduce the likelihood of disease progression and to prevent congenital transmission. Indeed, Chagas disease has been categorized as “the most neglected of the neglected diseases,” with lingering research and development gaps related to its treatment and diagnosis [16].

During the acute phase, diagnosis relies primarily on direct parasitological tests and secondarily on serological testing. Alternatively, during the chronic phase, diagnosis relies primarily on serological tests and secondarily on molecular tests, which are not readily available in primary health centers outside urban areas. Currently available diagnostic methods and medicines, however, are considered suboptimal for adequate control and treatment programs, reflecting the lackluster investment devoted to this disease [17]. At this time, the two available treatments, nifurtimox and benznidazole, are largely considered to be effective in the acute and early chronic infection and in preventing congenital transmission in children born to infected and treated mothers [18]. While there is a growing body of information to support the use of these medicines in the later stages of the disease, the effectiveness of these drugs outside the acute phase and the safety profile of these treatments need to be further established. Treatment is contraindicated during pregnancy, severe renal or hepatic insufficiency, and severe granulocytopenia and aplastic anemia in immunosuppressed patients, and thus, newer medicines with better risk-benefit profiles are necessary [17,19]. For diagnosis, there is a lack of effective tools for large-scale screening, point-of-care diagnosis, and monitoring patient’s response to antiparasitic treatment. In the case of asymptomatic acute infections, active search is preferred, involving direct parasitological methods and serology (immunoglobulin M [IgM] antibody anti-*T. cruzi*) for contacts or suspects. Serological tests are not considered to be reliable in endemic areas for diagnosis of acute asymptomatic infection because of the absence of good standardized commercial kits. Standard diagnostic protocols are hard to implement outside of large urban centers where one can anticipate a large number of infected individuals.

The complexity of the equipment that is required, the need for highly trained personnel, and the need for the patient to come to the health center more than once are among some of the most pressing constraints. Moreover, serodiagnosis in infants born to seropositive mothers has low positive predictive value due to the passive transfer of maternal anti-*T. cruzi* IgGs. At the same time, a small but sizeable number of infected newborns may be seronegative. Thus, it is recommended to conduct parasite search in this population using microhematocrit, hemoculture (HC), and PCR; none of these tests are easily performed outside laboratories performing tests of moderate and high complexity. Hence, developing new diagnostic tools that are easy to use and adapted to the needs of affected populations and to the reality of health systems based on primary health care will greatly improve the ability to control Chagas disease in the Americas [16,20].

A first and critical step to address the research and development gap is to establish a consensus on the desirable product profiles in different conditions of use. To foster and inform the development of these much needed tools, PAHO, in collaboration with the Drugs for Neglected Diseases initiative (DNDi), Médecins sans Frontières (MSF), and the Special Programme for Research and Training in Tropical Diseases (TDR), convened a multidisciplinary group of experts in Rio de Janeiro, Brazil (April 2010), to review the evidence and initiate discussions. The

meeting established the basis for the development of target product profiles (TPPs), which are reported in this paper.

Target Product Profile Consensus

The working group proposed TPPs for three different scenarios:

1. point-of-care diagnosis for patients in the acute phase (associated with congenital, vector, oral, transplant, or transfusion transmission and infection reactivation) ([Table 1](#));
2. point-of-care diagnosis for asymptomatic or symptomatic patients in the chronic phase ([Table 2](#)); and
3. assessment of response to antiparasitic treatment in the chronic phase ([Table 3](#)).

The group defined the following critical attributes for the different diagnostics methods according to the three specific clinical scenarios:

1. current need: as it relates to individual care, population-based programs, and situation of use;
2. medical conduct: why and how the diagnostic tool will be applied;
3. sampling: biological material, volume, preservation, and transportation process;
4. infrastructure needed: equipment, shipping procedures, and temperature control;
5. number of samples recommended per test and fractionation;
6. technical skills to perform the test;
7. testing site and turnaround time: time from obtaining samples to produce results;
8. test reading: as qualitative or quantitative;
9. taxonomic diagnosis: the capacity to differentiate parasite strains;
10. sensitivity: the ability to correctly identify all positive cases expressed in percentage; and
11. specificity: the ability to correctly identify all negative cases expressed in percentage (and the risk of cross-diagnosis of other prevalent diseases)

Establishing a TPP for the diagnostics and treatment monitoring of *T. cruzi* infection is an important step to guide research and development efforts.

In this paper, the TPPs are proposed according to the demands and needs of different population groups and today's diagnostics and treatment-monitoring challenges. These TPPs represent ideal features of a test adapted to the usual medical conditions in endemic countries. The proposed profiles take into consideration the ease of obtaining samples and the difficulties of transportation and processing them at the point of care, as well as the required infrastructure and the skills needed for performing the test. Irrespective of its specific characteristics and potential uses, the following attributes should be common to any ideal Chagas diagnostic test for public health use:

- Low cost, sustainable production and supply requirements, and based on simple manufacturing and distribution methods
- The diagnostic kits should contain all necessary materials for obtaining the sample and performing the test
- All reagents and other kit materials should be stable in prevalent climatic conditions

Table 1. TPP for point-of-care diagnosis for patients in the acute phase of Chagas disease.

Needs for Diagnosis	Medical Conduct	Samples and Sampling	Infrastructure	Technical Skills	Testing Site, Turnaround Time	Reading	Taxonomic Diagnosis	Sensitivity	Specificity
Congenital transmission	Serodiagnosis of pregnant women and women admitted at delivery living or born in endemic countries (knowing that >70% have no signs or symptoms)	Samples processed individually. (i) Maximum. 2 ml of cord or peripheral blood obtained specifically for diagnostic test; (ii) Blood sample collected for routine screening for infectious or metabolic diseases; (iii) Ideal: urine sample	(i) Ideal: processing at point of care; (ii) Less desirable: samples processed in a reference laboratory transported without cold chain	Good laboratory practices (GLP)–trained technical staff with quality certification. Screening conducted by staff who assisted the childbirth	Primary health centre (PHC), hospital or delivery institution. Ideal timing: <1 h, up to a maximum of 12 h from sampling	Qualitative	Single universal test should detect all circulating strains	>95%	100%. Ideal: integrated into routine health care screening (e.g., metabolic screening)
Vector and oral transmission	(i) Differential diagnosis for at risk population with febrile syndrome; (ii) Active search in cases of possible exposure (contacts)	Samples processed individually. (i) 2–5 mL blood or serum; (ii) Ideal: urine, saliva sample	(i) Ideal: processing at point of care; (ii) Less desirable: samples processed in a reference lab and transported without cold chain	GLP-trained technical staff with quality certification	PHC and/or community-based diagnosis facility. Ideal timing: <1 h from sampling	Qualitative/quantitative	Single universal test should detect all circulating strains	>95%	100%. Ideal: integrated into routine health care screening (e.g., metabolic screening). Should differentiate <i>T. cruzi</i> from <i>T. rangeli</i>
Reactivation of infection associated with immune suppression in organ transplants. Blood transfusion transmission	Active surveillance	Samples processed individually. Blood, cerebral spinal fluid, tissue from chagoma	(i) Ideal: processing at point-of-care; (ii) Less desirable: samples processed in a reference laboratory and transported without cold chain	GLP-trained technical staff with quality certification	Reference medical facility, blood banks, and hospital. Ideal timing: <1 h from sampling	Qualitative/quantitative	Single universal test should detect all circulating strains	>95%	100%. Ideal: integrated into routine screening. Should differentiate between <i>T. cruzi</i> and <i>T. rangeli</i> . In the case of diagnosis in central nervous system manifestations of HIV/AIDS, it should differentiate <i>T. cruzi</i> from other opportunistic infections, such as toxoplasmosis.

doi:10.1371/journal.pntd.0003697.t001

- Ease of disposal in accordance with standards of biosecurity
- Acceptability by the health system and target population

The consensus of the group is summarized in Tables 1–3.

Table 2. TPP for point-of-care diagnosis for patients in chronic phase of Chagas disease.

Needs for Diagnosis	Medical Conduct	Samples and Sampling	Infrastructure	Technical Skills	Testing Site, Turnaround Time	Reading	Taxonomic Diagnosis	Sensitivity	Specificity
Asymptomatic infected patients, referred symptomatic individuals, and positive blood donors	Active search in endemic/nonendemic and remote areas; prenatal screening	Samples processed individually. Ideal: saliva/urine; Alternative: whole blood, plasma or serum	Point of care, including community-based facility external to health center (no transportation required)	Adequately trained technical staff or community works with minimum quality certification standards	PHC and community setting (home, school, or community center); Ideal timing: <1 h from sampling	Qualitative	Single universal test should detect all circulating strains	Equal to or greater than standard serological tests	100%. No cross-reaction with other parasites (e.g., Leishmania, <i>T. rangeli</i>)

doi:10.1371/journal.pntd.0003697.t002

Discussion

Access to appropriate diagnostic tools is critical for individual care and public health control of Chagas disease. A series of publications have reviewed the current challenges related to diagnosis and monitoring of treatment response in patients affected with this disease [16,17,19,20–22]. Many have pointed to the need for an effective and affordable point-of-care test that can be used in endemic areas and administered by low-skilled health workers. This would greatly improve the detection of Chagas disease infections and facilitate appropriate treatment for affected populations, thus reducing the burden to individuals and to the health care system.

Detection of circulating parasites through a series of direct or indirect assays is the approach of choice for diagnostics during the acute phase of Chagas disease. In the acute phase, antiparasitic treatment can eliminate parasites and prevent chronic phase complications. A large proportion of patients remain undiagnosed at this stage, however, because of subclinical

Table 3. Assessment of response to anti-parasitic treatment in the chronic phase.

Needs for Diagnosis	Medical conduct	Samples and Sampling	Infrastructure	Technical Skills	Test Site	Reading	Taxonomic Diagnosis	Sensitivity	Specificity
Assess antiparasitic therapeutic response (based on persistent negativization of parasitemia or reduced parasitic load evaluation though molecular biology methods) ¹	Direct or indirect demonstration of the presence of the parasite in blood or tissue: (i) Before, during, and after treatment (end point >12 months); ii) Therapeutic failure (through the presence of the parasite or parasitic DNA/antigens in blood)	2–3 samples (before and after treatment), Ideal: blood (maximum of 5 mL [adults] and 2 mL [children]); Ideal: urine	Reference center, PHC and second level of care. Ideally: no cold chain; Acceptable: minimum cold chain (2°C–8°C); Unacceptable: conservation < 0°C (freezer)	GLP-trained technical staff with quality certification	Any health facility accessible and convenient for the patient; Maximum time for result: 1 week	Quantitative/qualitative	Ideal: taxonomic diagnosis (in the case of therapeutic failure); Acceptable: detects all circulating strains, but no taxonomic diagnosis	>95%	100%

¹There is no consensus on the definition of cure, but experts agree that the persistent negativization of parasitemia is the most appropriate marker [23].

doi:10.1371/journal.pntd.0003697.t003

presentation of infection and limited access of the affected populations to the health system. Moreover, diagnosis of congenital Chagas disease at the time of birth is considered ideal for timely and effective treatment, particularly in rural areas, since it is difficult for the mothers to take their children for confirmation of diagnosis at 10 months of age. However, there is some evidence showing that parasitic loads may increase during the first month of life and sensitivity of parasitological methods might be better at this period [23]; thus, more studies to assess cost-benefit of this issue are still needed.

In addition, new tools are needed for situations such as oral transmission outbreaks. These facts underline the importance of new diagnostic methods that can inform medical and public health decision-making in endemic countries. Indirect serological methods are currently used for diagnosis during the chronic or silent stage of the disease. A negative seroconversion has been used to assess treatment response, but it may involve a long follow-up period, in particular for chronically infected patients, which is impractical for public health interventions. There is a renewed interest in measuring treatment response to antiparasitic drugs during the chronic phase. While the treatment goal for infectious diseases is or should be pathogen elimination, there are other equally important therapeutic outcomes to be considered [24]. For some infections, such as AIDS, control and reduction of the pathogen burden are well-recognized strategies for converting a fatal disease into a chronically controlled disease, with the administration of appropriate treatments. Recent clinical trials may provide definitive evidence that patients with chronic phase Chagas disease can also benefit from treatment with antiparasitic medicines [21,24]. Current clinical trials during the indeterminate phase or in chronic cardiac Chagas disease patients are based on quantitative PCR (qPCR) methods to monitor the levels of circulating parasites and to detect therapeutic response. Although molecular based techniques are proven useful in a clinical trial setting [25], it is hard to envision their use, as they stand today, in the follow-up of extensive populations in the field. A necessary next step is the development of commercial kits based on recently standardized methods such as real-time PCR [25,26]. Other nucleic acid amplification methods such as loop-mediated isothermal amplification are currently under standardization [27]. However, these kits might have a more substantial impact on case management in more developed countries. Studies are under way to assess the negative predictive value of a PCR test to assess sterile cure (Isabela Ribeiro, personal communication). A recent publication [23] shows that there are several candidate markers, which together may fulfill acceptable criteria to indicate the efficacy of trypanocidal treatment.

Data from ongoing studies are considered essential to improve assessment of existing markers and to identify those for early follow-up of treated patients [23]. Thus, developing a more straightforward technique to directly or indirectly monitor parasitemia in chronic patients that is easier to standardize for wider use in clinical settings is necessary.

Innovative and promising strategies are currently being tested that may contribute to the development of new diagnostic tools for Chagas disease and that comply with several of the criteria included in the proposed TPP. In particular, the tests foreseen to be used at the primary health centre (PHC) or community level (as noted in column 6 of Tables 1 and 2) should comply with the ASSURED criteria [22]: (1) affordable by those at risk of infection; (2) sensitive (few false negatives); (3) specific (few false positives); (4) user friendly (simple to perform and requiring minimal training); (5) rapid (to enable treatment at first visit) and robust (does not require refrigerated storage); (6) equipment-free; and (7) delivered to those who need it. For other settings, more complex technologies such as enzyme-linked immunosorbent assay (ELISA) and PCR might be acceptable. Molecular methods applied to dried blood on filter paper, which has been carried out for triatomine samples [28,29], could enhance detection accuracy in acute and congenital Chagas disease cases. Moreover, serological methods based on low-volume samples are currently under standardization and validation [30]. Recently, a

nanoparticle-based assay using urine as the clinical sample has been developed for diagnosis of congenital Chagas disease [31].

Novel nucleic acid amplification approaches such as loop-mediated isothermal amplification, which are currently undergoing standardization and validation for other trypanosomatid infections, should be explored in Chagas disease diagnosis [32,33]. While flow cytometry has been shown to be a good platform, with high sensitivity and specificity for Chagas disease diagnosis and post-therapeutic cure monitoring [34,35], the use of flow cytometry-based devices to develop "point-of-care" TTPs does not seem to be a feasible approach, mainly considering the complexity and the nonportable nature of these devices.

The elimination of Chagas disease in the Americas requires long-term commitments and multidimensional strategies. Development of more appropriate diagnostic tools and treatment options can certainly accelerate and improve the chances of achieving this goal.

References

1. Pan American Health Organization, Chagas in the Americas for Public Health Workers; 2014. http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&Itemid=270&gid=24717&lang=en
2. Bern C, Kjos S, Yabsley MJ, Montgomery SP. *Trypanosoma cruzi* and Chagas' Disease in the United States. *Clin Microbiol Rev* (2011) 24: 655–681. doi: [10.1128/CMR.00005-11](https://doi.org/10.1128/CMR.00005-11) PMID: [21976603](https://pubmed.ncbi.nlm.nih.gov/21976603/)
3. Meymandi SK, Traina MI, El-Gassier A, Ngab T, Labedi M, et al. Prevalence of Chagas Disease in Los Angeles Latin American Immigrant Population with Cardiomyopathy. *Journal of Cardiac Failure* (2008) 14: S84.
4. Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD. The sero-prevalence of antibodies to *trypanosoma cruzi* in Latin American refugees and immigrants to Canada. *J Immigr Minor Health* (2007) 9: 43–47. PMID: [17006766](https://pubmed.ncbi.nlm.nih.gov/17006766/)
5. Frank M, Hegenscheid B, Janitschke K, Weinke T. Prevalence and epidemiological significance of *Trypanosoma cruzi* infection among Latin American immigrants in Berlin, Germany. *Infection* (1997) 25: 355–358. PMID: [9427054](https://pubmed.ncbi.nlm.nih.gov/9427054/)
6. Angheben A AM, Gobbi F, Marocco S, Monteiro G, Buonfrate D, Tais S, Talamo M, Zavarise G, Strohmeyer M, Bartalesi F, Mantella A, Di Tommaso M, Aiello KH, Veneruso G, Graziani G, Ferrari MM, Spreafico I, Bonifacio E, Gaiera G, Lanzafame M, Mascarello M, Cancrini G, Albajar-Viñas P, Bisoffi Z, Bartoloni A. (2011) Chagas disease in Italy: breaking an epidemiological silence. *Euro Surveill* 16: 19969. PMID: [21944554](https://pubmed.ncbi.nlm.nih.gov/21944554/)
7. Munoz J, Portus M, Corachan M, Fumado V, Gascon J. Congenital *Trypanosoma cruzi* infection in a non-endemic area. *Trans R Soc Trop Med Hyg* (2007) 101: 1161–1162. PMID: [17655897](https://pubmed.ncbi.nlm.nih.gov/17655897/)
8. Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, et al. Seroprevalence of *Trypanosoma cruzi* infection in at-risk blood donors in Catalonia (Spain). *Transfusion* (2008) 48: 1862–1868. doi: [10.1111/j.1537-2995.2008.01789.x](https://doi.org/10.1111/j.1537-2995.2008.01789.x) PMID: [18522707](https://pubmed.ncbi.nlm.nih.gov/18522707/)
9. Jackson Y, Myers C, Diana A, Marti HP, Wolff H, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. *Emerg Infect Dis* (2009) 15: 601–603. doi: [10.3201/eid1504.080438](https://doi.org/10.3201/eid1504.080438) PMID: [19331743](https://pubmed.ncbi.nlm.nih.gov/19331743/)
10. Martinez de Tejada B, Jackson Y, Paccolat C, Irion O. Congenital Chagas disease in Geneva: diagnostic and clinical aspects. *Rev Med Suisse* (2009) 5: 2091–2092, 2094–2096. PMID: [19947451](https://pubmed.ncbi.nlm.nih.gov/19947451/)
11. Brutus L, Santalla JA, Salas NA, Schneider D, Chippaux JP. Screening for congenital infection by *Trypanosoma cruzi* in France. *Bull Soc Pathol Exot* (2009) 102: 300–309. PMID: [20131424](https://pubmed.ncbi.nlm.nih.gov/20131424/)
12. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. *Acta Trop* (2010) 115: 22–27. doi: [10.1016/j.actatropica.2009.07.019](https://doi.org/10.1016/j.actatropica.2009.07.019) PMID: [19646412](https://pubmed.ncbi.nlm.nih.gov/19646412/)
13. Prata A. Clinical and epidemiological aspects of Chagas disease. *Lancet Infect Dis* (2001) 1: 92–100. PMID: [11871482](https://pubmed.ncbi.nlm.nih.gov/11871482/)
14. Ferreira MS, Borges AS (2002) Some aspects of protozoan infections in immunocompromised patients- a review. *Mem Inst Oswaldo Cruz* 97: 443–457. PMID: [12118272](https://pubmed.ncbi.nlm.nih.gov/12118272/)
15. World Health Organization. Chagas disease (American trypanosomiasis) fact sheet (revised in June 2010). *Weekly Epidem Rec* 85: 334–336.
16. World Health Organization. Research Priorities for Chagas Disease, Human African Trypanosomiasis, and Leishmaniasis. (2012) Geneva, Switzerland.

17. Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gurtler RE Eliminating Chagas disease: challenges and a roadmap. *BMJ* (2009) 338: b1283. doi: [10.1136/bmj.b1283](https://doi.org/10.1136/bmj.b1283) PMID: [19366739](https://pubmed.ncbi.nlm.nih.gov/19366739/)
18. Fabbro DL, Danesi E, Olivera V, Codebo MO, Denner S, et al. Trypanocide treatment of women infected with *Trypanosoma cruzi* and its effect on preventing congenital Chagas. *PLoS Negl Trop Dis* (2014) 8: e3312. doi: [10.1371/journal.pntd.0003312](https://doi.org/10.1371/journal.pntd.0003312) PMID: [25411847](https://pubmed.ncbi.nlm.nih.gov/25411847/)
19. Rassi A Jr., Rassi A, Marin-Neto JÁ. Chagas disease. *Lancet* (2010) 375: 1388–1402. doi: [10.1016/S0140-6736\(10\)60061-X](https://doi.org/10.1016/S0140-6736(10)60061-X) PMID: [20399979](https://pubmed.ncbi.nlm.nih.gov/20399979/)
20. Médecins Sans Frontières International meeting: new diagnostic tests are urgently needed to treat patients with Chagas disease. *Rev Soc Bras Med Trop* (2008) 41: 315–319. PMID: [18719818](https://pubmed.ncbi.nlm.nih.gov/18719818/)
21. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, et al. Chagas disease: changes in knowledge and management. *Lancet Infect Dis* (2010) 10: 556–570. doi: [10.1016/S1473-3099\(10\)70098-0](https://doi.org/10.1016/S1473-3099(10)70098-0) PMID: [20670903](https://pubmed.ncbi.nlm.nih.gov/20670903/)
22. Peeling RW and Mabey D. Point-of-care tests for diagnosing infections in the developing world.” *Clinical Microbiology and Infection* (2010), vol. 16, no. 8, pp. 1062–1069 doi: [10.1111/j.1469-0691.2010.03279.x](https://doi.org/10.1111/j.1469-0691.2010.03279.x) PMID: [20670288](https://pubmed.ncbi.nlm.nih.gov/20670288/)
23. Pinazo MJ, Thomas MC, Bua J, Perrone A, Schijman AG, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. *Expert Rev Anti Infect Ther* (2014) 12: 479–496. doi: [10.1586/14787210.2014.899150](https://doi.org/10.1586/14787210.2014.899150) PMID: [24621252](https://pubmed.ncbi.nlm.nih.gov/24621252/)
24. Viotti R, Alarcon de Noya B, Araujo-Jorge T, Grijalva MJ, Guhl F, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. *Antimicrob Agents Chemother* (2014) 58: 635–639. doi: [10.1128/AAC.01662-13](https://doi.org/10.1128/AAC.01662-13) PMID: [24247135](https://pubmed.ncbi.nlm.nih.gov/24247135/)
25. Duffy T, Cura CI, Ramirez JC, Abate T, Cayo NM, et al. Analytical performance of a multiplex Real-Time PCR assay using TaqMan probes for quantification of *Trypanosoma cruzi* satellite DNA in blood samples. *PLoS Negl Trop Dis* (2013) 7: e2000. doi: [10.1371/journal.pntd.0002000](https://doi.org/10.1371/journal.pntd.0002000) PMID: [23350002](https://pubmed.ncbi.nlm.nih.gov/23350002/)
26. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. *Clin Microbiol Rev* (2010) 3: 550–576 doi: [10.1128/CMR.00074-09](https://doi.org/10.1128/CMR.00074-09) PMID: [20610823](https://pubmed.ncbi.nlm.nih.gov/20610823/)
27. Thekisoe OM, Rodriguez CV, Rivas F, Coronel-Servian AM, Fukumoto S, et al. Detection of *Trypanosoma cruzi* and *T. rangeli* infections from *Rhodnius pallescens* bugs by loop-mediated isothermal amplification (LAMP). *Am J Trop Med Hyg* (2010) 82: 855–860. doi: [10.4269/ajtmh.2010.09-0533](https://doi.org/10.4269/ajtmh.2010.09-0533) PMID: [20439966](https://pubmed.ncbi.nlm.nih.gov/20439966/)
28. Dorn PL, Flores J, Brahney B, Gutierrez A, Rosales R, et al. Comparison of polymerase chain reaction on fresh tissue samples and fecal drops on filter paper for detection of *Trypanosoma cruzi* in *Rhodnius prolixus*. *Mem Inst Oswaldo Cruz* (2001) 96: 503–505. PMID: [11391422](https://pubmed.ncbi.nlm.nih.gov/11391422/)
29. Braz LM, Raiz-Junior R, Alarcon RS, Gakiya E, Amato-Neto V, et al. Suitability of a rapid DNA isolation and amplification for detection of *Trypanosoma cruzi* in *Triatoma infestans* dry fecal spots collected on filter paper. *Parasite* (2008) 15: 595–598. PMID: [19202767](https://pubmed.ncbi.nlm.nih.gov/19202767/)
30. Frade AF, Luquetti AO, Prata A, Ferreira AW. Western blotting method (TESAcruzi) as a supplemental test for confirming the presence of anti-*Trypanosoma cruzi* antibodies in finger prick blood samples from children aged 0–5 years in Brazil. *Acta Trop* (2011) 117: 10–13. doi: [10.1016/j.actatropica.2010.08.018](https://doi.org/10.1016/j.actatropica.2010.08.018) PMID: [20858452](https://pubmed.ncbi.nlm.nih.gov/20858452/)
31. Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, Ferrufino L, Sanchez G, et al. Use of a novel chagas urine nanoparticle test (chunap) for diagnosis of congenital chagas disease. *PLoS Negl Trop Dis* (2014) 8: e3211. doi: [10.1371/journal.pntd.0003211](https://doi.org/10.1371/journal.pntd.0003211) PMID: [25275534](https://pubmed.ncbi.nlm.nih.gov/25275534/)
32. Njiru ZK. Rapid and sensitive detection of human African trypanosomiasis by loop-mediated isothermal amplification combined with a lateral-flow dipstick. *Diagn Microbiol Infect Dis* (2011) 69: 205–209. doi: [10.1016/j.diagmicrobio.2010.08.026](https://doi.org/10.1016/j.diagmicrobio.2010.08.026) PMID: [21251567](https://pubmed.ncbi.nlm.nih.gov/21251567/)
33. Wastling SL, Picozzi K, Kakembo AS, Welburn SC. LAMP for human African trypanosomiasis: a comparative study of detection formats. *PLoS Negl Trop Dis* (2010) 4: e865. doi: [10.1371/journal.pntd.0000865](https://doi.org/10.1371/journal.pntd.0000865) PMID: [21072228](https://pubmed.ncbi.nlm.nih.gov/21072228/)
34. Matos CS, Coelho-Dos-Reis JG, Rassi A, Luquetti AO, Dias JC, et al. Applicability of an optimized non-conventional flow cytometry method to detect anti-*Trypanosoma cruzi* immunoglobulin G for the serological diagnosis and cure assessment following chemotherapeutic treatment of Chagas disease. *J Immunol Methods* (2011) 369: 22–32. doi: [10.1016/j.jim.2011.03.007](https://doi.org/10.1016/j.jim.2011.03.007) PMID: [21477591](https://pubmed.ncbi.nlm.nih.gov/21477591/)
35. Alessio GD, Cortes DF, Machado de Assis GF, Junior PA, Ferro EA, et al. Innovations in diagnosis and post-therapeutic monitoring of Chagas disease: Simultaneous flow cytometric detection of IgG1 antibodies anti-live amastigote, anti-live trypomastigote, and anti-fixed epimastigote forms of *Trypanosoma cruzi*. *J Immunol Methods* (2014) 413: 32–44. doi: [10.1016/j.jim.2014.07.005](https://doi.org/10.1016/j.jim.2014.07.005) PMID: [25064148](https://pubmed.ncbi.nlm.nih.gov/25064148/)